Novel vaccination strategies based on recombinant Mycobacterium bovis BCG

被引：14
作者：
Dietrich, G
Viret, JF
Hess, J
机构：
[1] Berna Biotech Ltd, CH-3018 Bern, Switzerland
[2] November AG, Erlangen, Germany
来源：
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY | 2003年 / 292卷 / 7-8期
关键词：
BCG vaccine; tuberculosis; heterologous antigen expression;
D O I：
10.1078/1438-4221-00227
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
In this manuscript, we will review the utilization of Mycobacterium bovis Bacille Calmette-Guerin (BCG) as a vaccine against tuberculosis (TB) and as a carrier system for heterologous antigens. BCG is one of the most widely used vaccines. Novel techniques in genome manipulation allow the construction of virulence-attenuated recombinant (r)-BCG strains that can be employed as homologous vaccines, or as heterologous antigen delivery systems, for priming pathogen-specific immunity against infectious diseases, including TB. Several approaches are available for heterologous antigen expression and compartmentalization in BCG and recent findings show the potential to modulate and direct the immune responses induced by r-BCG strains as desired. Recent achievements in complete genome analysis of various target pathogens, combined with a better understanding of protective pathogen-specific immune responses, form the basis for the rational design of a new generation of recombinant mycobacterial vaccines against a multitude of infectious diseases.
引用
收藏
页码：441 / 451
页数：11
相关论文
共 85 条
[21]   RECOMBINANT BCG THERAPY SUPPRESSES MELANOMA TUMOR-GROWTH [J].
DUDA, RB ;
YANG, H ;
DOOLEY, DD ;
ABUJAWDEH, G .
ANNALS OF SURGICAL ONCOLOGY, 1995, 2 (06) :542-549
[22]   Safety and immunogenicity of recombinant Bacille Calmette-Guerin (rBCG) expressing Burrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers:: a candidate Lyme disease vaccine [J].
Edelman, R ;
Palmer, K ;
Russ, KG ;
Secrest, HP ;
Becker, JAL ;
Bodison, SA ;
Perry, JG ;
Sills, AR ;
Barbour, AG ;
Luke, CJ ;
Hanson, MS ;
Stover, CK ;
Burlein, JE ;
Bansal, GP ;
Connor, EM ;
Koenig, S .
VACCINE, 1999, 17 (7-8) :904-914
[23]   Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas [J].
Elsässer-Beile, U ;
Gutzeit, O ;
Bauer, S ;
Katzenwadel, A ;
Schultze-Seemann, W ;
Wetterauer, U .
JOURNAL OF UROLOGY, 2000, 163 (01) :296-299
[24]   Intranasal vaccination of mice against infection with Mycobacterium tuberculosis [J].
Falero-Diaz, G ;
Challacombe, S ;
Banerjee, D ;
Douce, G ;
Boyd, A ;
Ivanyi, J .
VACCINE, 2000, 18 (28) :3223-3229
[25]   RECOMBINANT BACILLE CALMETTE-GUERIN PRIMING AGAINST MEASLES [J].
FENNELLY, GJ ;
FLYNN, JL ;
TERMEULEN, V ;
LIEBERT, UG ;
BLOOM, BR .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (03) :698-705
[26]  
Fine P.E. M., 1999, Issues relating to the use of BCG in immunization programs
[27]   BCG: the challenge continues [J].
Fine, PEM .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2001, 33 (04) :243-245
[28]   MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I-RESTRICTED T-CELLS ARE REQUIRED FOR RESISTANCE TO MYCOBACTERIUM-TUBERCULOSIS INFECTION [J].
FLYNN, JL ;
GOLDSTEIN, MM ;
TRIEBOLD, KJ ;
KOLLER, B ;
BLOOM, BR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (24) :12013-12017
[29]   Can a 'flawless' live vector vaccine strain be engineered? [J].
Galen, JE ;
Levine, MM .
TRENDS IN MICROBIOLOGY, 2001, 9 (08) :372-376
[30]   MYCOBACTERIUM-BOVIS BCG PRIMING INDUCES A STRONG POTENTIATION OF THE ANTIBODY-RESPONSE INDUCED BY RECOMBINANT BCG EXPRESSING A FOREIGN ANTIGEN [J].
GHEORGHIU, M ;
LAGRANDERIE, MRR ;
GICQUEL, BME ;
LECLERC, CD .
INFECTION AND IMMUNITY, 1994, 62 (10) :4287-4295
123456789